CY1124552T1 - Θειενοπυριδινες και βενζοθειοφαινια χρησιμα ως αναστολεις irak4 - Google Patents

Θειενοπυριδινες και βενζοθειοφαινια χρησιμα ως αναστολεις irak4

Info

Publication number
CY1124552T1
CY1124552T1 CY20211100874T CY211100874T CY1124552T1 CY 1124552 T1 CY1124552 T1 CY 1124552T1 CY 20211100874 T CY20211100874 T CY 20211100874T CY 211100874 T CY211100874 T CY 211100874T CY 1124552 T1 CY1124552 T1 CY 1124552T1
Authority
CY
Cyprus
Prior art keywords
benzothiophenies
thienopyridines
compounds
irak4 inhibitors
treatment
Prior art date
Application number
CY20211100874T
Other languages
Greek (el)
English (en)
Inventor
Saleem Ahmad
Lidet A. Negash
John Hynes
Ling Li
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1124552T1 publication Critical patent/CY1124552T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY20211100874T 2017-05-11 2021-10-07 Θειενοπυριδινες και βενζοθειοφαινια χρησιμα ως αναστολεις irak4 CY1124552T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762504956P 2017-05-11 2017-05-11
PCT/US2018/031945 WO2018209012A1 (en) 2017-05-11 2018-05-10 Thienopyridines and benzothiophenes useful as irak4 inhibitors

Publications (1)

Publication Number Publication Date
CY1124552T1 true CY1124552T1 (el) 2022-07-22

Family

ID=62245511

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100874T CY1124552T1 (el) 2017-05-11 2021-10-07 Θειενοπυριδινες και βενζοθειοφαινια χρησιμα ως αναστολεις irak4

Country Status (29)

Country Link
US (1) US10829496B2 (cg-RX-API-DMAC7.html)
EP (1) EP3621960B1 (cg-RX-API-DMAC7.html)
JP (1) JP7154229B2 (cg-RX-API-DMAC7.html)
KR (1) KR102604900B1 (cg-RX-API-DMAC7.html)
CN (1) CN110612298B (cg-RX-API-DMAC7.html)
AR (1) AR111689A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018265130B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019023290A2 (cg-RX-API-DMAC7.html)
CA (1) CA3062602A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019003198A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019012494A2 (cg-RX-API-DMAC7.html)
CY (1) CY1124552T1 (cg-RX-API-DMAC7.html)
DK (1) DK3621960T3 (cg-RX-API-DMAC7.html)
EA (1) EA039189B1 (cg-RX-API-DMAC7.html)
ES (1) ES2889926T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211583T1 (cg-RX-API-DMAC7.html)
HU (1) HUE056493T2 (cg-RX-API-DMAC7.html)
IL (1) IL270494B (cg-RX-API-DMAC7.html)
LT (1) LT3621960T (cg-RX-API-DMAC7.html)
MX (1) MX2019012929A (cg-RX-API-DMAC7.html)
MY (1) MY200228A (cg-RX-API-DMAC7.html)
PE (1) PE20191817A1 (cg-RX-API-DMAC7.html)
PL (1) PL3621960T3 (cg-RX-API-DMAC7.html)
PT (1) PT3621960T (cg-RX-API-DMAC7.html)
RS (1) RS62430B1 (cg-RX-API-DMAC7.html)
SI (1) SI3621960T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100568T1 (cg-RX-API-DMAC7.html)
TW (1) TW201900640A (cg-RX-API-DMAC7.html)
WO (1) WO2018209012A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
MX2020003190A (es) 2017-09-22 2020-11-11 Kymera Therapeutics Inc Degradadores de proteinas y usos de los mismos.
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
AU2019389174A1 (en) 2018-11-30 2021-07-01 Kymera Therapeutics, Inc. Irak degraders and uses thereof
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
US12558427B2 (en) 2019-07-17 2026-02-24 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
JP7620611B2 (ja) 2019-07-18 2025-01-23 ブリストル-マイヤーズ スクイブ カンパニー IRAK4阻害剤として有用なピラゾロ[3,4-d]ピロロ[1,2-b]ピリダジニル化合物
WO2021011724A1 (en) 2019-07-18 2021-01-21 Bristol-Myers Squibb Company Tricyclic heteroaryl compounds useful as irak4 inhibitors
JP7573596B2 (ja) * 2019-07-23 2024-10-25 ブリストル-マイヤーズ スクイブ カンパニー Irak4阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物
EP4010317B1 (en) 2019-08-06 2024-06-19 Bristol-Myers Squibb Company Bicyclic heterocyclic compounds useful as irak4 inhibitors
CN114206874B (zh) 2019-08-13 2024-08-02 百时美施贵宝公司 可用作irak4抑制剂的双环杂芳基化合物
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
CA3161878A1 (en) 2019-12-17 2021-06-24 Matthew M. Weiss Irak degraders and uses thereof
WO2021158495A1 (en) 2020-02-03 2021-08-12 Bristol-Myers Squibb Company Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors
CN111285844B (zh) * 2020-02-24 2022-08-12 河南师范大学 具有生物活性的苯并噻吩取代酰胺类化合物及其合成方法和应用
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
EP4161521A4 (en) 2020-06-03 2024-07-10 Kymera Therapeutics, Inc. DEUTERED IRAQ DEGRADERS AND USES THEREOF
AR124547A1 (es) 2020-12-30 2023-04-05 Kymera Therapeutics Inc Degradadores de irak y sus usos
WO2022174268A1 (en) 2021-02-15 2022-08-18 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
JP2024540080A (ja) 2021-10-29 2024-10-31 カイメラ セラピューティクス, インコーポレイテッド Irak4分解剤およびその合成
EP4472967A4 (en) 2022-01-31 2026-04-15 Kymera Therapeutics Inc Iraqi Degradation Agents and Their Uses

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8627698D0 (en) * 1986-11-20 1986-12-17 Boots Co Plc Therapeutic agents
CA2450769A1 (en) 2001-06-15 2002-12-27 Vertex Pharmaceuticals Incorporated 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
ES2373226T3 (es) 2002-06-28 2012-02-01 Astellas Pharma Inc. Derivado de diaminopirimidincarboxamida.
EP1590341B1 (en) 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
EP1651636A1 (en) 2003-07-10 2006-05-03 Neurogen Corporation Substituted heterocyclic diarylamine analogues
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
AR053158A1 (es) 2005-03-09 2007-04-25 Schering Corp Compuestos para inhibir la actividad de quinesina de ksp
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US8003662B2 (en) 2006-01-30 2011-08-23 Array Biopharma, Inc. Heterobicyclic thiophene compounds and methods of use
CN101679376A (zh) 2007-06-08 2010-03-24 拜尔农科股份有限公司 杀真菌剂杂环-嘧啶基-氨基衍生物
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
JP5254693B2 (ja) 2008-07-30 2013-08-07 三菱重工業株式会社 Ni基合金用溶接材料
EP2361902A4 (en) 2008-11-21 2012-04-25 Astellas Pharma Inc 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG
KR101361027B1 (ko) 2008-11-28 2014-02-11 코와 가부시키가이샤 피리딘-3-카르복시아미드 유도체
NZ596479A (en) 2009-05-22 2014-01-31 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CN102458402B (zh) 2009-06-12 2013-10-02 百时美施贵宝公司 用作激酶调节剂的烟酰胺化合物
MX2012002591A (es) 2009-09-03 2012-04-02 Allergan Inc Compuestos como moduladores de tirosina cinasas.
BR112012010220A2 (pt) 2009-10-30 2021-02-23 Janssen Pharmaceutical N.V. piridinas fenóxi-substituídas como modulares do receptor opioide
EP2532656A1 (en) 2010-02-01 2012-12-12 Nippon Chemiphar Co., Ltd. Gpr119 agonist
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
AU2012249240A1 (en) 2011-04-29 2013-11-07 Icahn School Of Medicine At Mount Sinai Kinase inhibitors
ES2686500T3 (es) 2012-01-13 2018-10-18 Bristol-Myers Squibb Company Compuestos de piridilo sustituidos con heterocíclicos, útiles como inhibidores de cinasas
WO2013106614A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
EP2802579B1 (en) 2012-01-13 2016-04-13 Bristol-Myers Squibb Company Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
CN104781251B (zh) 2012-11-08 2016-12-14 百时美施贵宝公司 可作为激酶调节剂的经双环杂环取代的吡啶基化合物
EP2922841B8 (en) 2012-11-08 2017-08-02 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
AU2013341200A1 (en) 2012-11-08 2015-07-02 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
PL3536685T3 (pl) 2014-04-04 2022-05-16 Pfizer Inc. Bicykliczne skondensowane związki heteroarylowe lub arylowe i ich zastosowanie jako inhibitory IRAK4
US10155765B2 (en) 2015-03-12 2018-12-18 Merck Sharp & Dohme Corp. Carboxamide inhibitors of IRAK4 activity
US10040802B2 (en) * 2015-03-12 2018-08-07 Merck Sharp & Dohme Corp. Thienopyrazine inhibitors of IRAK4 activity
EP3313844B1 (en) 2015-06-24 2020-08-26 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
CN107849039B (zh) 2015-06-24 2020-07-03 百时美施贵宝公司 经杂芳基取代的氨基吡啶化合物
HRP20210472T1 (hr) 2015-08-27 2021-05-14 Pfizer Inc. Biciklički kondenzirani heteroarilni ili arilni spojevi kao modulatori irak4

Also Published As

Publication number Publication date
MX2019012929A (es) 2020-01-14
ES2889926T3 (es) 2022-01-14
HUE056493T2 (hu) 2022-02-28
BR112019023290A2 (pt) 2020-06-16
US10829496B2 (en) 2020-11-10
PL3621960T3 (pl) 2021-11-08
JP7154229B2 (ja) 2022-10-17
PE20191817A1 (es) 2019-12-27
CL2019003198A1 (es) 2020-03-20
EA039189B1 (ru) 2021-12-15
IL270494B (en) 2022-04-01
US20200062777A1 (en) 2020-02-27
CA3062602A1 (en) 2018-11-15
MY200228A (en) 2023-12-15
DK3621960T3 (da) 2021-09-27
TW201900640A (zh) 2019-01-01
EP3621960B1 (en) 2021-08-04
SMT202100568T1 (it) 2021-11-12
LT3621960T (lt) 2021-10-11
CO2019012494A2 (es) 2020-01-17
EP3621960A1 (en) 2020-03-18
RS62430B1 (sr) 2021-11-30
AU2018265130A1 (en) 2020-01-02
KR20200004871A (ko) 2020-01-14
CN110612298B (zh) 2023-05-05
HRP20211583T1 (hr) 2022-01-07
AU2018265130B2 (en) 2022-03-24
SI3621960T1 (sl) 2021-11-30
WO2018209012A1 (en) 2018-11-15
KR102604900B1 (ko) 2023-11-21
PT3621960T (pt) 2021-09-16
JP2020519596A (ja) 2020-07-02
AR111689A1 (es) 2019-08-07
CN110612298A (zh) 2019-12-24
EA201992674A1 (ru) 2020-04-06

Similar Documents

Publication Publication Date Title
MY200228A (en) Thienopyridines and benzothiophenes useful as irak4 inhibitors
CY1125214T1 (el) Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
CY1124496T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CY1120834T1 (el) Δικυκλικες αζωτουχες ενωσεις ως αγωνιστες μουσκαρινικων υποδοχεων μ1
CY1124187T1 (el) Ετεροκυκλικα αμιδια ως αναστολεις κινασης
CY1124055T1 (el) Ετεροκυκλικες ενωσεις ως ανοσοδιαμορφωτες
CY1123645T1 (el) Δικυκλικα παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1123223T1 (el) Παραγωγα πυραζολιου ως αναστολεις καλλικρεϊνης πλασματος
CY1123994T1 (el) Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4
CY1124798T1 (el) Υποκατεστημενα παραγωγα καρβονουκλεοζιδιων χρησιμα ως παραγοντες κατα των καρκινων
MX2021008533A (es) Inhibidores de la pcsk9 y metodos de uso de los mismos.
CY1120361T1 (el) Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido)
CY1124173T1 (el) Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες
CY1125230T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CY1124620T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CO2018008761A2 (es) Derivados de maitansinoide, conjugados de los mismos métodos de uso
MA51290A (fr) Nouvelles pyridopyrimidinones à substitution benzylamino et dérivés à utiliser en tant qu'inhibiteurs de sos1
CY1123374T1 (el) Αμιδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων
MX2019007416A (es) Derivados de benzooxazol como inmunomoduladores.
CY1123349T1 (el) Ενωσεις 6-ετεροκυκλυλ-4-μορφολιν-4-υλπυρiδιν-2-οnhς χρησιμες για τη θεραπεια καρκινου και διαβητη
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
PE20210452A1 (es) Inhibidores de la arginasa
CY1121677T1 (el) Ενωσεις διμεθυλοβενζοϊκου οξεος
EA201992320A1 (ru) Пиперидины в качестве ковалентных ингибиторов менина
CY1124450T1 (el) Νουκλεοτιδια βητα-νικοτινικου εστερα και διεργασιες για την παρασκευη αυτων